Results 61 to 70 of about 67,273 (233)

Management of imatinib-resistant CML patients [PDF]

, 2007
Imatinib has had marked impact on outcomes in chronic myelogenous leukemia (CML) patients for all stages of the disease and is endorsed by international treatment guidelines as the first line option.
Branford S, Burger H, Burgess MR, Cortes J, Crossman LC, Donato NJ, Druker BJ, Gambacorti-Passerini C, Giles F, Hochhaus A, Hughes TP, Iacobucci I, Kantarjian H, Lahaye T, Mahon FX, Melo JV, O'Hare T, Quintas-Cardama A, Rousselot P, Sleijfer S, Soverini S, Weisberg E   +21 more
core   +1 more source

Long‐Term Quality of Life in 1777 Persons With Hodgkin Lymphoma and 6166 Matched Comparators

American Journal of Hematology, EarlyView.
ABSTRACT Survival has improved substantially for patients with Hodgkin lymphoma (HL), but long‐term quality of life (QoL) remains incompletely understood. This was a Danish, nationwide, cross‐sectional study of QoL among persons with a diagnosis of HL matched 1:10 to general population comparators.
Sissel Johanne Godtfredsen, Joachim Baech, Mikkel Porsborg Andersen, Harman Yonis, Paw Jensen, Peter Kamper, Jacob H. Christensen, Rasmus Bo‐Dahl Sørensen, Martin Hutchings, Christian Torp‐Pedersen, Peter Sogaard, Henrik Boggild, Kristian H. Kragholm, Tarec C. El‐Galaly   +13 more
wiley   +1 more source

Real‐World Outcomes of FLAG‐Ida Regimen in 1079 Adult Patients With First Relapsed/Refractory AML: A PETHEMA Study

American Journal of Hematology, EarlyView.
ABSTRACT In a large multicenter real‐world cohort, we aimed to evaluate outcomes of FLAG‐Ida salvage therapy for relapsed/refractory (R/R) acute myeloid leukemia (AML) and validated the SALFLAGE prognostic score. We analyzed 1079 adults with R/R AML treated across 112 PETHEMA institutions over 26 years (1998–2024), including patients with primary ...
Gaspar Aspas Requena, Rebeca Rodríguez‐Veiga, Cristina Gil, Carmen Botella, Eliana Aguiar, Fernanda Trigo, Mercedes Colorado, Teresa del Bernal del Castillo, Eva Barragan, Mar Tormo, Eduardo Rodríguez Arbolí, Josefina Serrano López, Raimundo García Boyero, Tamara Castaño, Pilar Herrera Puente, Mónica A. Romero Riquelme, María J. Sayas Lloris, Lorenzo Algarra‐Algarra, Carlos Rodriguez‐Medina, Claudia L. Sossa Melo, Jorge Labrador Gomez, Susana Vives, Olga Salamero, María Luz Amigo, Marta Valero Nuñez, Christine Rojas, Francisca Bass, María García‐Fortes, Belén Vidriales Vicente, Marta Polo, Celina Benavente, María D. Madrigal, Marcela Espinoza, Manuel Pérez‐Encinas, María L. Amador Barciela, Guiomar Bautista, Antonio Solana‐Altabella, Isabel Cano‐Ferri, Rafael Colmenares, Patricia García‐Ramírez, Francisco Ibáñez Alis, Manuel Barrios García, Gabriela Rodríguez‐Macías, Miguel López, Ana Yurena Oliva Hernández, Carlos Javier Cerveró, David Martínez‐Cuadrón, Pedro Chorão, Juan M. Bergua Burgues, Pau Montesinos   +49 more
wiley   +1 more source

Inhibition of mTOR-dependent autophagy sensitizes leukemic cells to cytarabine-induced apoptotic death.

PLoS ONE, 2014
The present study investigated the role of autophagy, a cellular self-digestion process, in the cytotoxicity of antileukemic drug cytarabine towards human leukemic cell lines (REH, HL-60, MOLT-4) and peripheral blood mononuclear cells from leukemic ...
Mihajlo Bosnjak, Biljana Ristic, Katarina Arsikin, Aleksandar Mircic, Violeta Suzin-Zivkovic, Vladimir Perovic, Andrija Bogdanovic, Verica Paunovic, Ivanka Markovic, Vladimir Bumbasirevic, Vladimir Trajkovic, Ljubica Harhaji-Trajkovic   +11 more
doaj   +1 more source

Post CAR‐T Measurable Residual Disease Monitoring in Mantle Cell Lymphoma Enables Early Detection of Disease Relapse

American Journal of Hematology, EarlyView.
ABSTRACT CD19‐directed chimeric antigen receptor (CAR) T‐cell therapy has transformed outcomes for patients with relapsed or refractory (r/r) mantle cell lymphoma (MCL), yet more than 40% relapse within one year. Early identification of patients at risk for progression could inform post CAR‐T surveillance and consolidation strategies.
Snegha Ananth, Neha Agarwal, Bita Sahaf, Allison Jacob, Lik Wee Lee, Heidi Simmons, Ilan Kirsch, Sushma Bharadwaj, Wen‐kai Weng, Melody Smith, Saurabh Dahiya, David Miklos, Matthew J. Frank   +12 more
wiley   +1 more source

Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia [PDF]

, 2003
BACKGROUND: Sensitization of leukemic cells with hematopoietic growth factors may enhance the cytotoxicity of chemotherapy in acute myeloid leukemia (AML).
Boogaerts, M., Daenen, S., de Greef, G., Ferrant, A., Fey, M., Gmür, J., Gratwohl, A., Huijgens, P., Kovacsovics, T., Löwenberg, B., Schouten, H., Sonneveld, P., Theobald, M., van Putten, W., Verdonck, L.   +14 more
core   +8 more sources

Tribulus terrestris L. Hydroalcoholic Extract Revokes the Hepatotoxicity Induced by Cytarabine in Male Wistar Rats [PDF]

Pharmaceutical and Biomedical Research
Background: Liver is a critical organ that detoxifies poisonous compounds, metabolizes drugs, and excretes waste products. Liver is sensitive to damage and anticancer therapy.
Niloufar Darbandi, Ruba Fadhel Jabbar
doaj  

Finite-Duration Venetoclax/Azacitidine Followed by Umbilical Cord Blood Infusion Improves Outcomes in Frail Elderly Patients With Untreated Acute Myeloid Leukemia-A Pilot Study. [PDF]

Cancer Med
ABSTRACT Background Continuous venetoclax‐azacitidine (VA) therapy is currently the major intervention for elderly or unfit acute myeloid leukemia (AML) patients. However, moderate chemotherapy with finite‐duration VA could achieve comparable or superior efficacy to infinite‐duration VA.
Ye L, Xie M, Xu G, Mei C, Hu C, Zhou X, Ren Y, Ma L, Yang C, Qian J, Jin J, Tong H.   +11 more
europepmc   +2 more sources

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia—A comprehensive review

British Journal of Clinical Pharmacology, EarlyView.
While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis, Leiah J. Brigitha, Lidwien M. Hanff, Alwin D. R. Huitema, Inge M. van der Sluis, Meta H. M. Diekstra   +5 more
wiley   +1 more source

microRNAs and Acute Myeloid Leukemia Chemoresistance: A Mechanistic Overview

Frontiers in Oncology, 2017
Up until the early 2000s, a functional role for microRNAs (miRNAs) was yet to be elucidated. With the advent of increasingly high-throughput and precise RNA-sequencing techniques within the last two decades, it has become well established that miRNAs can
Martino Marco Gabra, Leonardo Salmena, Leonardo Salmena   +2 more
doaj   +1 more source